Document Detail

A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol.
MedLine Citation:
PMID:  11399385     Owner:  NLM     Status:  MEDLINE    
We describe a case of withdrawal from the gamma hydroxybutyric acid (GHB) precursors gamma butyrolactone and 1,4-butanediol. Symptoms included visual hallucinations, tachycardia, tremor, nystagmus, and diaphoresis. Administration of benzodiazepines and phenobarbital successfully treated the withdrawal symptoms. As predicted from the metabolism of gamma butyrolactone and 1,4-butanediol to GHB, the symptoms were nearly identical to those reported from GHB withdrawal. Because GHB is now illegal in the United States, individuals have begun abusing the legal and easier to acquire GHB precursors. More frequent cases of both abuse and withdrawal from these GHB precursors can be expected.
A B Schneir; B T Ly; R F Clark
Related Documents :
21519845 - Treatment of langerhans cell histiocytosis bone lesions with zoledronic acid: a case se...
4061715 - Utilization of case definitions and laboratory reporting in the surveillance of notifia...
16506545 - Quick control of bubonic plague outbreak in uttar kashi, india.
8846485 - Epidemiology and clinical characteristics of acute flaccid paralysis associated with no...
23589725 - The significance of the site of origin in primary peritoneal carcinosarcoma: case repor...
19958565 - Aggressive angiomyxoma of larynx: case report and literature review.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  The Journal of emergency medicine     Volume:  21     ISSN:  0736-4679     ISO Abbreviation:  J Emerg Med     Publication Date:  2001 Jul 
Date Detail:
Created Date:  2001-06-11     Completed Date:  2001-07-26     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8412174     Medline TA:  J Emerg Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  31-3     Citation Subset:  IM    
Division of Medical Toxicology, Department of Emergency Medicine, UCSD Medical Center, California Poison Control System-San Diego Division, 200 West Arbor Drive, San Diego, CA 92103-8925, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
4-Butyrolactone / adverse effects*
Anticonvulsants / therapeutic use
Diazepam / therapeutic use
Drug Therapy, Combination
Lorazepam / therapeutic use
Phenobarbital / therapeutic use
Substance Withdrawal Syndrome / drug therapy,  etiology*
United States
Reg. No./Substance:
0/Anticonvulsants; 439-14-5/Diazepam; 50-06-6/Phenobarbital; 846-49-1/Lorazepam; 96-48-0/4-Butyrolactone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cimetidine-induced dystonic reaction.
Next Document:  The prehospital electrocardiogram.